Selective Piperidine Derivatives Targeting LXRβ Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Alzheimer's disease and related inflammatory and metabolic disorders often have peripheral adverse lipid effects due to the activation of hepatic LXRα, while LXRβ agonists are needed to target neurodegenerative diseases without these side effects.
Innovation Solution
Development of selective piperidine derivatives that act as LXRβ agonists, which can be used to treat Alzheimer's disease, inflammatory diseases, and other disorders related to cholesterol and lipid metabolism, avoiding the peripheral adverse effects associated with LXRα activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual LXRα/β small agonist molecules are used to treat metabolic disorders, then cholesterol absorption is reduced and lipid homeostasis is improved, but liver steatosis and hyperlipidemia occur due to activation of hepatic LXRα
Solution Approach 1:
The patent applies local quality by creating selective LXRβ agonists that specifically target the LXRβ receptor subtype in the brain and peripheral tissues, while avoiding activation of LXRα in the liver. This selective activation approach allows beneficial effects in target tissues without the harmful effects in the liver, resolving the contradiction between improving cholesterol metabolism and avoiding liver steatosis.
Solution Approach 2:
The patent segments the LXR receptor system into two distinct subtypes (LXRα and LXRβ) with different tissue distributions and functions. By developing selective agonists that target only LXRβ, the patent separates the beneficial metabolic effects from the harmful hepatic effects, allowing independent optimization of each receptor subtype's activation.
2Reliability
If LXRα activation is used to treat hyperlipidemia and atherosclerosis, then cholesterol efflux is increased, but peripheral adverse lipid effects occur
Solution Approach 1:
The patent applies local quality by directing LXR activation specifically to LXRβ-expressing tissues (brain, peripheral tissues) while avoiding LXRα activation in peripheral organs. This spatial selectivity maintains cholesterol efflux benefits in the brain and peripheral tissues while preventing adverse lipid effects in peripheral organs.
3Object-affected harmful factors
If selective LXRβ agonists are developed to avoid peripheral adverse effects, then neurodegenerative diseases can be treated without liver toxicity, but compound complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters (substituents, functional groups, steric configurations) of the piperidine derivative core structure to achieve selective LXRβ binding. By optimizing these chemical parameters, the patent achieves high selectivity and potency while managing compound complexity through structured modification rather than entirely new molecular architectures.
Data Source
AI summary
In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.